15 March 2018
BARHEMSYS™ (formerly BAREMSIS®) Prevents Post-Operative Nausea & Vomiting In High-Risk Patients (published in Anesthesiology)
Positive Phase 3 Clinical Trial Published in Peer-reviewed Journal, Anesthesiology
Armagh, UK – 15 March 2018: Lan Chem Laboratories UK (“Lan Chem Laboratories”, the “Company” or the “Group”), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, announces that data and analysis from its Phase 3 prophylaxis trial with intravenous amisulpride (BAREMSIS®) in combination with standard antiemetics have been published in the Online First edition of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists (ASA) (Kranke et al.). Positive headline results were first announced by the Company in January 2016.
The Phase 3 trial demonstrated that BAREMSIS is safe and resulted in a statistically significant reduction in the emergence of post-operative nausea & vomiting (PONV) when given in combination with an antiemetic drug from another class to adult patients undergoing elective procedures who are at high risk of PONV.
“Tens of millions of Americans undergo surgery each year and many suffer with nausea and vomiting after their operation,” said Peter Kranke, M.D., Professor of Anaesthesiology at the University of Würzburg in Germany and the trial’s lead investigator. “PONV contributes to patient distress, can delay recovery after surgery and increases hospital costs. Patients with multiple risk factors for PONV require a multimodal approach for its prevention, including using a combination of anti-nausea drugs with different mechanisms of action, since it cannot be predicted which pathway(s) will be active in a patient.”
Risk factors for PONV (“Apfel risk factors”) include being female, having a prior history of PONV or motion sickness, non-smokers and those expected to use opioids after surgery for pain. Without effective preventive treatment, nausea and/or vomiting in the 24 hours after surgical operations under anaesthesia may occur in 60 to 80 percent of high-risk patients with three or four of these recognised risk factors.
“International consensus guidelines recommend the use of combinations of antiemetics from different mechanistic classes for the prevention of PONV in high-risk patients, acknowledging the multiple biological pathways that are implicated in PONV,” added Dr Gabriel Fox, Lan Chem Laboratories’s Chief Medical Officer. “Currently two classes of antiemetics are predominantly used to prevent PONV in these patients: 5HT3 antagonists (usually ondansetron) and corticosteroids (usually dexamethasone). However, a safe and effective third mechanism antiemetic is required in high-risk patients or those where the act of retching and vomiting may be detrimental to their clinical progress such as upper GI surgery. The clinical results we have seen with BAREMSIS (a dopamine antagonist) across our extensive Phase 3 development programme, provide strong evidence that BAREMSIS has the potential to fulfil this need.”
Professor T.J. Gan, Chair of the Department of Anesthesiology of Stony Brook School of Medicine and Co-Founder and Past President of the American Society of Enhanced Recovery (ASER), commented: “Even when multiple antiemetics are used for prophylaxis, there is still an appreciable failure rate in highest-risk patients. The option to add BAREMSIS to current therapy could be valuable in reducing the incidence of PONV and enhancing patient recovery after surgery. This is a key part of delivering optimal post-operative outcomes in the United States.”
Summary of the trial and results
The Phase 3 study was a double-blind, randomised, placebo-controlled trial at 29 sites in France, Germany and the UK. It included 1,147 adult patients undergoing elective surgery under general anaesthesia, who had three or four Apfel risk factors. Patients all received one standard antiemetic (approximately half received ondansetron and half dexamethasone) and were randomly assigned to receive in addition either 5 mg of BAREMSIS intravenously (572 patients) or a matching placebo (575 patients), prior to their surgery.
The researchers found 57.7% of patients receiving BAREMSIS had a complete response — defined as no vomiting or need for medication to relieve nausea — in the 24 hours after surgery, compared with 46.6% of those receiving the placebo (P < 0.001).
A benefit of BAREMSIS over placebo was seen in both three– (62% vs 54.3%, P = 0.013) and four– risk factor patients (50.8% vs 36.7%, P < 0.001) and when combined with either a corticosteroid or ondansetron.
Overall, vomiting (13.8% vs. 20%), any nausea (50% vs. 58.3%), significant nausea (37.1% vs. 47.7%), and those requiring fast-acting medication to relieve vomiting (40.9% vs. 49.4%) were significantly lower in the BAREMSIS group. Adverse events occurred no more frequently with BAREMSIS than with placebo.